CAJ | 학술논문

目的分析70例慢性粒细胞白血病（ CML）的治疗现状。方法回顾分析1998年4月至2014年3月起病的70例患者的临床资料及治疗反应。结果全部为Ph染色体阳性CML，男女性各35例，中位年龄50岁。70例患者中，使用酪氨酸激酶抑制剂（ TKI）伊马替尼、干扰素和羟基脲的患者分别占35.7%、35.7%和52.9%，接受异基因造血干细胞移植（ allo-HSCT）的患者占11.4%。随访时间从4月至16年，中位随访27个月。TKI治疗组3年总生存（OS）率是85.7%，而羟基脲（和/或）干扰素组及异基因造血干细胞移植病人3年OS率分别是46.4%和75.0%，与TKI 治疗组比较的P值分别是0.04和0.19。结论 CML是一种骨髓增殖性疾病，随着TKI作为一线治疗用药的越来越广泛的临床应用，使得CML患者的治疗效果和生存质量均得到明显改善。
목적분석70례만성립세포백혈병（ CML）적치료현상。방법회고분석1998년4월지2014년3월기병적70례환자적림상자료급치료반응。결과전부위Ph염색체양성CML，남녀성각35례，중위년령50세。70례환자중，사용락안산격매억제제（ TKI）이마체니、간우소화간기뇨적환자분별점35.7%、35.7%화52.9%，접수이기인조혈간세포이식（ allo-HSCT）적환자점11.4%。수방시간종4월지16년，중위수방27개월。TKI치료조3년총생존（OS）솔시85.7%，이간기뇨（화/혹）간우소조급이기인조혈간세포이식병인3년OS솔분별시46.4%화75.0%，여TKI 치료조비교적P치분별시0.04화0.19。결론 CML시일충골수증식성질병，수착TKI작위일선치료용약적월래월엄범적림상응용，사득CML환자적치료효과화생존질량균득도명현개선。
Objective To investigate the clinical characteristics and treatment response of 70 patients with chronic myeloid leukemia ( CML). Methods Clinical data,treatment efficacy and outcomes of 70 cases of CML enrolled from April 1998 to March 2014 were retrospective-ly analyzed. Results All the patients were Ph chromosome positive. Median age of onset were 50 years old. Male and female were 35 patients re-spectively. Of all 70 patients with the treatment of tyrosine-kinase inhibitor,interferon-alpha and hydroxyurea treatment account for 35. 7%, 35. 7% and 52. 9%,respectively. The allogeneic hematopoietic stem cell transplantation(allo-HSCT)account for 11. 4%. The time of follow up is from 4 months to 16 years. The median follow up time is 27 months. 3 year overall survival rate(OS)was 85. 7% in TKI treatment group. 3 years OS rates in hydroxyurea and interferon group were 46. 4% and 75%,respectively. Compared with TKI group,p value were 0. 04 and 0. 19 in the interferon and hydroxyurea group. Conclusion CML is a myeloproliferative disorder of hematopoietic stem cells. TKIs are now the first line of treatment for CML. Therefore,the treatment for CML changed significantly.